Abstract:Highlights • Biomaterial-enhanced Treg therapy has the potential to transform organ transplantation and autoimmune disease treatments by enhancing Treg efficacy. • Interventions utilizing biomaterials can improve Treg migration, stability, and suppressive abilities in target tissues, maximizing therapeutic impact. • The safety and efficacy demonstrated by biomaterial-based Treg therapy lay the groundwork for future treatments in this field. • Biomaterial properties are crucial in guiding the design of platforms that support Treg function, thereby enhancing treatment precision. • Biomaterials provide diverse options for modulating immune responses, expanding the potential applications of Treg therapy. Regulatory T cells (Tregs) are crucial for preserving tolerance in the body, rendering Treg immunotherapy a promising treatment option for both organ transplants and autoimmune diseases. Presently, organ transplant recipients must undergo lifelong immunosuppression to prevent allograft rejection, while autoimmune disorders lack definitive cures. In the last years, there has been notable advancement in comprehending the biology of both antigen-specific and polyclonal Tregs. Clinical trials involving Tregs have demonstrated their safety and effectiveness. To maximize the efficacy of Treg immunotherapy, it is essential for these cells to migrate to specific target tissues, maintain stability within local organs, bolster their suppressive capabilities, and ensure their intended function's longevity. In pursuit of these goals, the utilization of biomaterials emerges as an attractive supportive strategy for Treg immunotherapy in addressing these challenges. As a result, the prospect of employing biomaterial-enhanced Treg immunotherapy holds tremendous promise as a treatment option for organ transplant recipients and individuals grappling with autoimmune diseases in the near future. This paper introduces strategies based on biomaterial-assisted Treg immunotherapy to enhance transplant medicine and autoimmune treatments. Graphical abstract Download : Download high-res image (316KB) Download : Download full-size image

Biomaterial-enabled induction of pancreatic-specific regulatory T cells through distinct signal transduction pathways

Dissecting regulatory T cell expansion using polymer microparticles presenting defined ratios of self-antigen and regulatory cues

Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment

Leverage Biomaterials to Modulate Immunity for Type 1 Diabetes.

Rational Engineering of Islet Tolerance via Biomaterial-Mediated Immune Modulation

Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype In Vitro and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses

Immunoprotection of Cellular Transplants for Autoimmune Type 1 Diabetes through Local Drug Delivery

Generation of islet antigen-specific engineered Treg for use in T1D therapy via homology-directed gene editing of conventional CD4+ T cells

Tolerogenic Ag-PLG Nanoparticles Induce Tregs to Suppress Activated Diabetogenic CD4 and CD8 T Cells.

Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis

Tolerogenic Vaccine Composited with Islet Derived Multipeptides and Cyclosporin A Induces pTreg and Prevents Type 1 Diabetes in Murine Model.

Antigen-specific nanoparticle tolerance treatment actively induces both FoxP3- and IL-10-dependent regulatory mechanisms

Bio-inspired controlled release for regulatory T cell recruitment in vivo (144.3)

Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes

Anti-TCR Mab Induces Peripheral Tolerance to Alloantigens and Delays Islet Allograft Rejection in Autoimmune Diabetic NOD Mice.

GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes

Nano‐Targeted Delivery of Immune Therapeutics in type 1 Diabetes

Transcriptional re-programming of insulin B-chain epitope-specific T-follicular helper cells into anti-diabetogenic T-regulatory type-1 cells

Regulatory CD4+ T cells redirected against pathogenic CD8+ T cells protect NOD mice from development of autoimmune diabetes

Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision

Long-term Tolerance to Islet Transplantation via Targeted Reduction of beta cell-specific T cells.